Controversies in the Management of Early-Stage Hodgkin Lymphoma

Presenter: Ranjana H. Advani
Restricted access

Early-stage Hodgkin lymphoma is a highly curable malignancy, but controversies surrounding treatment recommendations persist due to the sheer number of treatment choices available, as well as the effort to balance risk versus benefit for each individual patient. The gold standard for treatment has evolved over the years. Currently, in the PET era, fine-tuning therapy approaches is largely focused on avoiding giving too much therapy to patients with a negative interim PET and too little therapy to those with a positive interim PET. Careful patient selection for therapy has become increasingly important, as patient risk factors for early-stage disease are variably defined by German Hodgkin Study Group, EORTC, and NCCN criteria.

Disclosures: Dr. Advani has disclosed that she has received consulting fees from ADC Therapeutics, Celgene Corporation, Genentech, Inc./Roche Laboratories, Inc., Gilead Sciences, Inc., Portola Pharmaceuticals, Inc., Sanofi-Aventis U.S., Seattle Genetics, Inc., Kura Oncology, Inc, Karyopharm, and Takeda Pharmaceuticals North America, Inc.; and received institutional grant/research support from Forty Seven, Inc., Genentech, Inc./Roche Laboratories, Inc., Janssen Pharmaceutica Products, LP, Kura Oncology, Inc., Merck & Co., Inc., Millennium Pharmaceuticals, Inc., Regeneron Pharmaceuticals, Inc., and Seattle Genetics, Inc.

Correspondence: Ranjana H. Advani, MD, Stanford Cancer Institute, 875 Blake Wilbur Drive, Stanford, CA 94305. Email: radvani@stanford.edu
  • 1.

    van Leeuwen FE, Ng AK. Late sequelae in Hodgkin lymphoma survivors. Hematol Oncol 2017;35(Suppl 1):6066.

  • 2.

    Patel CG, Michaelson E, Chen Y, et al. . Reduced mortality risk in the recent era in early-stage Hodgkin lymphoma patients treated with radiation therapy with or without chemotherapy. Int J Radiat Oncol Biol Phys 2018;100:498506.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Fuchs M, Goergen H, Kobe C, et al. . Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group. J Clin Oncol 2019;37:28352845.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 4.

    André MPE, Girinsky T, Federico M, et al. . Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 2017;35:17861794.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 5.

    Radford J, Illidge T, Counsell N, et al. . Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. N Engl J Med 2015;372:15981607.

  • 6.

    Kumar A, Casulo C, Yahalom J et al. . Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma. Blood 2016;128:14581464.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Brockelmann PJ, Goergen H, Keller U, et al. . Efficacy of nivolumab and AVD in early-stage unfavorable classic Hodgkin lymphoma: the randomized phase 2 German Hodgkin Study Group NIVAHL trial. JAMA Oncol 2020;6:872880.

    • Crossref
    • Search Google Scholar
    • Export Citation
  • 8.

    Cottereau AS, Versari A, Loft A, et al. . Prognostic value of baseline metabolic tumor volume in early-stage Hodgkin lymphoma in the standard arm of the H10 trial. Blood 2018;131:14561463.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Goyal G, Tella SH, Funni S, et al. . Association between facility volume and mortality of patients with classic Hodgkin lymphoma. Cancer 2020;126:757764.


All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 512 512 5
PDF Downloads 99 99 6
EPUB Downloads 0 0 0